CTLA4 and squamous cell carcinoma: In the neoadjuvant scenario, a phase II clinical trial evaluated nivolumab activity with an anti-CTLA-4 agent compared to nivolumab monotherapy in 29 patients with squamous cell carcinoma in the oral cavity (OC-SCC) (Table 2).